Rivaroxaban Viatris (previously Rivaroxaban Mylan) Kesatuan Eropah - Norway - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Sufenta 50 mikrog/ ml Norway - Norway - Statens legemiddelverk

sufenta 50 mikrog/ ml

piramal critical care b.v. - sufentanilsitrat - injeksjonsvæske, oppløsning - 50 mikrog/ ml

Sufenta 5 mikrog/ ml Norway - Norway - Statens legemiddelverk

sufenta 5 mikrog/ ml

piramal critical care b.v. - sufentanilsitrat - injeksjonsvæske, oppløsning - 5 mikrog/ ml

Morphine Orion 10 mg/ ml Norway - Norway - Statens legemiddelverk

morphine orion 10 mg/ ml

orion corporation - espoo - morfinhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml

Lidocaine Accord 10 mg/ ml Norway - Norway - Statens legemiddelverk

lidocaine accord 10 mg/ ml

accord healthcare b.v. - lidokainhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml

Lidocaine Accord 20 mg/ ml Norway - Norway - Statens legemiddelverk

lidocaine accord 20 mg/ ml

accord healthcare b.v. - lidokainhydroklorid - injeksjonsvæske, oppløsning - 20 mg/ ml

Xylocain 20 mg/ ml Norway - Norway - Statens legemiddelverk

xylocain 20 mg/ ml

aspen pharma trading limited - lidokainhydroklorid - injeksjonsvæske, oppløsning - 20 mg/ ml

Xylocain 10 mg/ ml Norway - Norway - Statens legemiddelverk

xylocain 10 mg/ ml

aspen pharma trading limited - lidokainhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml

Actilyse 20 mg Norway - Norway - Statens legemiddelverk

actilyse 20 mg

boehringer ingelheim international gmbh - alteplase - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 20 mg

Actilyse 10 mg Norway - Norway - Statens legemiddelverk

actilyse 10 mg

boehringer ingelheim international gmbh - alteplase - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 10 mg